UnitedHealthcare GI Motility Policy Update Coverage

Coverage Criteria and Diagnostic Test Policy

Indications for Gastric Electrical Stimulation (GES)

Covered when ALL of the following are met

GES coverage indication: Gastric electrical stimulation (GES) therapy is proven and medically necessary for treating refractory Gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to Gastroparesis of diabetic or idiopathic etiology.

Refer to the U.S. Food and Drug Administration (FDA) section for information regarding FDA labeling and Humanitarian Device Exemption (HDE) for GES.

Unproven / Not Medically Necessary Diagnostic Procedures

Not medically necessary (unproven) when ANY of the following are used for diagnosis

Unproven diagnostic procedures: Magnetic Resonance Imaging (MRI) Defecography for evaluating Constipation and Anorectal or pelvic floor disorders; Cutaneous, mucous, or serosal Electrogastrography, electroenterography, or body surface gastric mapping (e.g., Gastric Alimetry System, G-Tech Gut Tracker wireless patch system) for diagnosing intestinal or gastric disorders including Gastroparesis; Esophageal Mucosal Integrity Testing by electrical impedance (e.g., MiVu Mucosal Integrity Testing System) for the diagnosis of gastroesophageal reflux disease (GERD), eosinophilic esophagitis (EoE), and nonacid reflux disease (non-GERD), or for the monitoring of treatment response in GERD and EoE.

Listed as unproven and not medically necessary due to insufficient evidence of efficacy.

GES — conditional consideration — GES may be considered under limited circumstances according to professional societies and evidence assessments

GES may be considered under limited circumstances according to professional societies and evidence assessments:

Society-based conditional consideration for GES: GES may be considered for medically refractory diabetic or idiopathic gastroparesis as a humanitarian use device (ACG) and for patients with refractory/intractable nausea and vomiting who have failed standard therapy and are not on opioids (AGA).

Based on low-quality evidence and conditional recommendations; Hayes HTA finds effectiveness uncertain and calls for more RCTs.

MR defecography — diagnostic context — Role in pelvic floor/defecatory disorders

MR defecography role in pelvic floor/defecatory disorders:

When to use MR defecography: MR defecography can be useful when anorectal manometry (ARM) and balloon expulsion test (BET) are equivocal or when additional soft-tissue detail is needed for multidisciplinary or preoperative planning; MRD may serve as a triage test but does not replace evacuation proctography (EP) as the reference standard and may have lower technical success or sensitivity for some findings compared with fluoroscopic defecography.

Consider limitations including variable techniques, supine imaging, and potential under-detection of structural findings compared with fluoroscopic methods.

EGG/BSGM — investigational / insufficient evidence — Electrogastrography / body surface gastric mapping

Electrogastrography / body surface gastric mapping:

EGG/BSGM evidence and use: Current evidence is insufficient to support routine clinical use of cutaneous electrogastrography (EGG), electroenterography, or body surface gastric mapping (BSGM, e.g., Gastric Alimetry) for diagnosis of gastric disorders or to improve patient outcomes; standardized recording, analysis, and interpretation protocols and additional clinical validity and clinical utility studies are needed.

ECRI and recent systematic reviews conclude available evidence is very low quality and heterogeneous.

Evidence-based coverage considerations — Coverage stance based on available evidence in this document segment

Coverage stance based on available evidence in this document segment:

EGG/BSGM general stance: Studies fail to provide convincing evidence that EGG or BSGM are accurate for diagnosis of gastric disorders or that their use improves patient management or outcomes; additional standardized studies assessing diagnostic accuracy and clinical utility are needed.

Supported by systematic reviews and ECRI assessment.

Gastric Alimetry specific: Published evidence for the Gastric Alimetry System is very low quality; diagnostic accuracy and clinical utility are not established and further studies are needed.

ECRI Clinical Evidence Assessment (2024).

Esophageal mucosal integrity testing (MI): Limited and small studies suggest MI can distinguish GERD, EoE, and non-GERD, but clinical validity and clinical utility are insufficiently established; MI testing is not supported as a sole diagnostic screening tool.

Hayes and ECRI reviews; Patel et al. and Choksi et al. studies.

Not Medically Necessary — Esophageal Mucosal Integrity Testing — Not medically necessary when used for the following indications

Not medically necessary when used for the following indications:

Esophageal mucosal impedance testing NMN: Esophageal Mucosal Integrity Testing by electrical impedance (e.g., MiVu) for the diagnosis of gastroesophageal reflux disease (GERD), eosinophilic esophagitis (EoE), and nonacid reflux disease (non-GERD), or for monitoring of treatment response in GERD and EoE are unproven and not medically necessary due to insufficient evidence of efficacy.

Policy history (10/01/2025) added this coverage stance based on limited evidence.

This Medical Policy does not apply to certain states where a state-specific policy or guideline governs coverage. See state-specific references for Idaho, Indiana, Kansas, Kentucky, Louisiana, Nebraska, New Jersey, New Mexico, North Carolina, Ohio, Pennsylvania, and Tennessee. Note: language was updated to explicitly indicate the policy does not apply to Nebraska and North Carolina (refer to the respective state-specific policy versions).

When a requested service falls within one of the excluded states, reviewers should follow the applicable state-specific policy or guideline rather than this national policy.

Health technology assessments and systematic reviews have concluded that the evidence supporting gastric electrical stimulation (GES) for treatment of gastroparesis is limited and of low quality. The Hayes HTA and subsequent systematic reviews found inconsistent results across studies, small randomized trial data, and methodological limitations that leave effectiveness uncertain.

Because randomized and blinded data are few and open-label observational series dominate the literature, guideline panels have issued only conditional or limited recommendations that GES be considered primarily for medically refractory diabetic or idiopathic gastroparesis after failure of standard therapies.

Per the FDA labeling for the Enterra™ gastric electrical stimulation system (Humanitarian Device Exemption), the device should not be used in patients with gastric obstruction or pseudo-obstruction, prior gastric resection, prior fundoplication, eating disorders, history of seizures, primary swallowing disorders, chemical dependency, or psychogenic vomiting.

This Medical Policy does not apply to the states of Nebraska and North Carolina. For members in those states, refer to the applicable state-specific policy versions for coverage determinations.

Tests and procedures explicitly listed in this policy as unproven or not medically necessary include: Magnetic Resonance Imaging (MRI) Defecography for evaluation of constipation and anorectal/pelvic floor disorders; cutaneous, mucous, or serosal electrogastrography (EGG), electroenterography, and body surface gastric mapping (e.g., Gastric Alimetry System, G‑Tech Gut Tracker wireless patch system) for diagnosing intestinal or gastric disorders including gastroparesis; and esophageal mucosal integrity testing by electrical impedance (e.g., MiVu) for diagnosis/monitoring of GERD and EoE.

MR defecography may be used selectively when anorectal manometry and balloon expulsion testing are equivocal or when additional soft-tissue detail is required for planning, but it is listed here among procedures with limited or inconsistent evidence for routine diagnostic use.

Electrogastrography (EGG) and related electroenterography techniques have not demonstrated convincing diagnostic accuracy or a positive impact on clinical management or patient outcomes. Systematic reviews and evidence assessments report heterogeneous protocols, low-quality studies, and insufficient data to support widespread clinical use.

Current evidence does not support routine clinical use of body surface gastric mapping (BSGM)/EGG or mucosal impedance testing as definitive diagnostic tools. ECRI and other reviews found very low quality or limited studies for systems such as the Gastric Alimetry and MiVu devices and concluded that larger clinical validity and clinical utility studies are required before these tests can be recommended for routine practice.

Esophageal mucosal impedance testing (e.g., the MiVu Mucosal Integrity Testing System) is considered unproven and not medically necessary for the diagnosis of gastroesophageal reflux disease (GERD), eosinophilic esophagitis (EoE), nonacid reflux, or for monitoring treatment response in GERD and EoE due to limited and low-quality published evidence and uncertain clinical utility.

Applicable and Updated Procedure Codes

Applicable Codes (group 1)CPT

0779T	Gastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report.
0868T	High-resolution gastric electrophysiology mapping with simultaneous patient-symptom profiling, with interpretation and report.
43499	Unlisted procedure, esophagus.
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.

Applicable Codes (group 2)CPT

43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open.
43882	Revision or removal of gastric neurostimulator electrodes, antrum, open.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array.
72195	Magnetic resonance (e.g., proton) imaging, pelvis; without contrast material(s).
72196	Magnetic resonance (e.g., proton) imaging, pelvis; with contrast material(s).
72197	Magnetic resonance (e.g., proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences.
76498	Unlisted magnetic resonance procedure (e.g., diagnostic, interventional).
91132	Electrogastrography, diagnostic, transcutaneous.
91133	Electrogastrography, diagnostic, transcutaneous; with provocative testing.

Applicable CPT Codes AddedCPT

43499	Added CPT code (unspecified procedure, esophagus).
76498	Added CPT code (unlisted magnetic resonance procedure).

Applicable CPT/HCPCS Codes RemovedmixedNot Covered

74270	Removed
76496	Removed
91117	Removed
91120	Removed
91122	Removed
A9286	Removed
A9900	Removed
A9999	Removed
E1399	Removed

Anorectal angle (ARA) change — MR defecography diagnostic finding

ARA change valueARA change < 1.5 degrees suggested as a diagnostic finding for dyssynergic defecation in a MR defecography study (Thanaracthanon et al., 2023).

ContextFinding derived from retrospective single-center MR defecography study of 46 adults with chronic constipation evaluating nine MR parameters for dyssynergic defecation.

Diagnostic performance noteAuthors reported ARA change among parameters with statistically significant differences between dyssynergic defecation and non-DD groups and noted high specificity for ARA change.

LimitationsSingle-center retrospective design, small sample size, no comparison test, and need for independent validation and prospective studies.

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization may be required for listed procedures including implantation, revision, or removal of gastric neurostimulator components. Providers should verify plan-specific prior authorization (PA) requirements before scheduling services.

Verify PA for codes related to gastric neurostimulator implantation, revision, and removal.
Check state/plan-specific PA rules and medical necessity documentation requirements.

Billing Rule

Billing/Coding — Applicable Codes Added

Applicable procedure and diagnostic codes have been added or updated; include these codes on PA requests and claims and confirm whether they require prior authorization. Listing a code does not guarantee coverage—benefit determination is subject to federal, state, or contractual requirements.

Clinical Background and Scope

Gastroparesis is a disorder of delayed gastric emptying that commonly presents with nausea, vomiting, early satiety, bloating, and abdominal pain. Diabetes is a frequent underlying cause. Diagnosis requires objective evidence of delayed gastric emptying (radioscintigraphic gastric emptying testing is the reference standard), while electrogastrography and body surface mapping record gastric myoelectrical activity but currently have limited, investigational roles in routine clinical diagnosis.

Definitions

Gastroparesis — definition

DefinitionA digestive disorder in which the motility of the stomach is either abnormal or absent; also known as delayed gastric emptying.

Common causes/clinical featuresSymptoms include nausea, vomiting, early satiety, bloating, and abdominal pain; diabetes is a common cause.

Diagnostic requirementDiagnosis requires objective evidence of delayed gastric emptying (scintigraphy is the reference standard).

Electrogastrography (EGG) — definition

DefinitionA non-invasive method for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach; the surface recording is called an electrogastrogram.

Purpose

OpenPayer

Gastrointestinal Motility Disorders, Diagnosis and Treatment

Coverage Criteria and Diagnostic Test Policy

Applicable and Updated Procedure Codes

Provider Requirements, Prior Authorization, and Documentation

Clinical Background and Scope

Definitions